Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly sales of $160.00 million which beat the analyst consensus estimate of $143.84 million by 11.23 percent. This is a 20.30 percent increase over sales of $133.00 million the same period last year.
Credit Suisse Maintains Outperform on Johnson Controls Intl, Raises Price Target to $86
Credit Suisse analyst John Walsh maintains Johnson Controls Intl (NYSE:JCI) with a Outperform and raises the price target from $85 to $86.
